Most Read Articles
17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.
Pearl Toh, 24 Jul 2018
SGLT-2* inhibitors and GLP-1** agonists were associated with better survival compared with DPP-4*** inhibitors or control (placebo or no treatment) in patients with type 2 diabetes (T2D) who were inadequately controlled on metformin, according to a large network meta-analysis of 236 randomized trials.

Canagliflozin not associated with increased risk for fracture in T2D patients

12 Jan 2019

Use of canagliflozin, compared with a glucagon-like peptide-1 (GLP-1) agonist, does not increase the risk for fracture in middle-aged patients with type 2 diabetes and relatively low fracture risk, according to a recent study.

A total of 79,964 patients (mean age 55 years; 48 percent female; average baseline haemoglobin A1c, 8.7 percent; 27 percent were prescribed insulin) initiating use of canagliflozin were included in this study. They were matched to the same number of patients initiating use of a GLP-1 agonist.

The rate of humerus, forearm, pelvis or hip fracture that needed intervention was comparable among patients in the canagliflozin (2.2 events per 1,000 person-years) and GLP-1 agonist groups (2.3 events per 1,000 person-years; overall hazard ratio [HR], 0.98; 95 percent CI, 0.75–1.26).

There was also comparable risk for pelvic, hip, humerus, radius, ulna, carpal, metacarpal, metatarsal or ankle fracture between canagliflozin (14.5 events per 1,000 person-years) and GLP-1 agonist groups (16.1 events per 1,000 person-years; overall HR, 0.92; 0.83–1.02).

In this population-based new-user cohort study, the authors estimated risk for nonvertebral fracture among new users of canagliflozin vs GLP-1 agonist. Two US commercial healthcare databases providing data on >70 million patients were accessed from March 2013 to October 2015.

The primary outcome was a composite of humerus, forearm, pelvis, or hip fracture requiring intervention, while secondary outcomes included fractures at other sites. The authors performed a fixed-effects meta-analysis that pooled results from the databases to provide an overall HR.

The study was limited by unmeasured confounding, measurement error and low fracture rate.

“Sodium–glucose cotransporter-2 inhibitors promote glycosuria, resulting in possible effects on calcium, phosphate, and vitamin D homeostasis. Canagliflozin is associated with decreased bone mineral density and a potential increased risk for fracture,” the authors noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.
Pearl Toh, 24 Jul 2018
SGLT-2* inhibitors and GLP-1** agonists were associated with better survival compared with DPP-4*** inhibitors or control (placebo or no treatment) in patients with type 2 diabetes (T2D) who were inadequately controlled on metformin, according to a large network meta-analysis of 236 randomized trials.